Colorado Family's Hope Dashed as Rare Drug Trial Ceases

Rare Disease Week highlighted the struggles of families seeking treatments, including a Colorado family whose son's clinical trial was unexpectedly terminated. Caleb Burgess, diagnosed with fibrodysplasia ossificans progressiva (FOP), an extremely rare genetic disorder causing bone to replace soft tissues, found significant relief from an experimental drug.

For nearly two years, Caleb experienced diminished pain, reduced swelling, and an improved quality of life. This progress offered a sense of normalcy and hope. However, in December, the drug's manufacturer announced the discontinuation of the clinical trial, citing failure to meet the required endpoint for bone growth reduction.

The Burgess family is now sharing their experience to urge policymakers to re-evaluate how rare disease research and drug development are assessed, especially when trials yield quality-of-life improvements. They hope for greater flexibility in regulatory processes to ensure continued access to medications that demonstrably work for patients, even if they don't meet all statistical targets. The FDA recently held a town hall addressing these concerns, affirming a commitment to patient safety and reducing regulatory hurdles.